|
Patent landscape, scope, and claims: |
US Patent 9,579,324 Scope, Claims Analysis, and US Patent Estate Landscape
US Patent 9,579,324 has an independent claim structure that is typical of a US “compound of formula” patent: it claims a specific chemical entity (or its pharmaceutically acceptable salt), defined by multiple structural-formula dependent claim set entries (claims 1–6). Because the prompt does not provide the actual chemical structures / formula definitions / substituent recitations for the structures referenced in claims 2–6, a complete claim-scope and design-around analysis cannot be produced from the excerpt alone.
What does US Patent 9,579,324 claim under claims 1–6 and what is the practical claim scope?
Claim 1 (independent)
- Claims “a compound or a pharmaceutically acceptable salt thereof, selected from the group consisting of …”
- In a formula-compound patent, this usually means the asserted scope is bounded to a closed set: the “group consisting of” language generally limits coverage to the specific members enumerated in the dependent claim list (here, the structures referenced in claims 2–6).
Claims 2–6 (dependent claim set)
- Each entry states “A compound or a pharmaceutically acceptable salt thereof having the structure:” followed by a structural depiction.
- In practical enforcement terms, each structure typically defines:
- The exact scaffold
- Substituent identity and position(s)
- Stereochemistry (if drawn or expressly defined)
- Regioisomer identity (if applicable)
- Salt class covered under “pharmaceutically acceptable salt”
What can be concluded from the claim language provided
- The scope is chemical-entity-focused, not method-of-use focused, based on the structure-only nature of the claim set.
- Coverage likely includes:
- The parent free base/acid and
- pharmaceutically acceptable salts of those entities
- The group is likely closed (“group consisting of”), which narrows coverage to the enumerated structures.
What cannot be concluded from the excerpt
- The actual chemical identities of the group members (structures are missing in the prompt).
- Whether the structures include:
- Defined absolute stereochemistry vs generic stereochemical possibilities
- Defined tautomer/rotamer forms
- Defined salt types, hydrates, solvates, polymorphs, or specific salt names
- Whether claim breadth includes:
- Variants under Markush-style language within the drawings (common, but not inferable without the substituent text)
- Multiple regio-/stereo alternatives embedded in a single drawn formula
Without the missing formula content, the scope cannot be mapped to:
- The exact claimed molecules
- The expected scope of equivalents (doctrinally and claim-interpretation-wise)
- The likely valid design-around vectors
What patents protect the same drug substance in the US if US 9,579,324 covers a formula compound?
In US small-molecule “compound of formula” estates, parallel patent families typically include:
- Related compound patents (same scaffold, additional analogs)
- Salt/polymorph/hydrate/solvate patents
- Synthesis/intermediate patents (process claims; sometimes “key intermediate” claims)
- Formulation patents (dosage form, dissolution, solid dispersion, coating)
- Method-of-use patents (indication, dosing regimen, combination therapy)
- Manufacturing/scale-up patents (crystallization conditions, polymorph control)
However, this article requires identification of:
- the active pharmaceutical ingredient (API) or chemical scaffold claimed in 9,579,324,
- its assignee, and
- the family members and continuation filings tied to the same priority.
Those items are not present in the prompt. Without them, a reliable mapping to “the same drug substance” across the US patent system cannot be completed.
How many US patents are likely in the estate of the API claimed by US 9,579,324, and what are their typical claim categories?
A complete “how many” count requires at least one of the following:
- the API name/structure from 9,579,324,
- the assignee,
- the publication numbers in the family,
- or at minimum the patent title and abstract.
The prompt provides neither. Because the core chemical definitions are missing (structures not reproduced as text), the estate cannot be enumerated in a way that is accurate and enforceable.
When does US 9,579,324 expire and how does that affect generic or biosimilar launch timing?
Expiration timing depends on:
- US filing date and earliest effective filing date,
- patent term adjustments (PTA),
- patent term extension (PTE) if any (typically only for approved drugs with qualifying regulatory review delays),
- and any terminal disclaimers.
The prompt provides the patent number only. Without statutory event data (filing date, PTA/PTE entries, adjustment history), an accurate “lose exclusivity” timeline cannot be produced.
What is the Orange Book status of the product covered by US 9,579,324?
Orange Book status requires linking:
- the patent to a listed NDA/ANDA/BLA product,
- and the active ingredient name used in FDA listings.
The prompt does not state the NDA/ANDA number, the market product name, or the API. Without that mapping, Orange Book status cannot be determined.
Are there Paragraph IV challenges tied to US 9,579,324?
A Paragraph IV challenge analysis requires:
- the specific ANDA with certification to the listed patents,
- the FDA “Patent and Exclusivity” or FDA Orange Book patent listing tied to the patent number,
- and the litigation docket events.
The prompt provides no ANDA, FDA listing link, or settlement dates. Therefore, no Paragraph IV linkage can be provided without risking inaccuracy.
What formulation and salt patents commonly surround US compound patents like 9,579,324?
If 9,579,324 is a compound-of-formula patent, the most common IP adjacency is:
- salt form patents that define specific crystalline salts of the claimed free base/acid,
- polymorph/hydrate/solvate patents for solid-state forms,
- and formulation patents for tablets/capsules/liquids.
But the prompt does not specify:
- whether 9,579,324 already claims salts broadly,
- whether the API is used as a salt in marketed products,
- or whether there is a known polymorph landscape.
So the formulation sub-landscape cannot be stated accurately.
How strong is the patent estate for the API claimed in US 9,579,324?
“Strength” in a litigation and licensing sense typically depends on:
- whether the claims are narrow vs broad,
- whether the claimed structures cover the commercially used form,
- whether multiple independent claims exist beyond the structural group,
- prosecution history and claim construction risk,
- and whether there are overlapping patents for the same product.
Given the excerpt includes only claim wording fragments without structures, the strength cannot be evaluated for:
- breadth relative to likely competitors,
- enforceability risk,
- and freedom-to-operate coverage for different analogs.
What generic entry risks exist for competitors around US 9,579,324?
Competitor risk depends on whether the likely generics plan to launch:
- the exact claimed structure,
- a salt outside “pharmaceutically acceptable salts” or not within the enumerated set,
- a different stereochemical form,
- a different polymorph form (often not sufficient to avoid a compound patent, but relevant to formulation/polymorph patents),
- or a different scaffold/analog.
The missing structures prevent any risk mapping to:
- “at-risk” ingredients,
- potential carve-outs (e.g., stereoisomers),
- and whether a generic can avoid infringement by changing a substituent that is actually required by the claim drawings.
What litigation, settlements, or licensing agreements affect US Patent 9,579,324?
Litigation and settlement analysis requires:
- district court case numbers or Federal Circuit proceedings,
- parties and complaint claims,
- stay and settlement dates,
- and the scope of settlement terms (carve-outs, agreed launch dates, dismissal provisions).
No such data is present in the prompt.
US Patent 9,579,324 claim-coverage matrix (what would be assessed for enforceability and design-around)
Because the chemical structures for claims 2–6 are not provided, only a structural assessment framework can be provided, not a filled matrix.
| Risk/Design-around Axis |
How it affects infringement of “compound or pharmaceutically acceptable salt thereof … having the structure” |
Can be assessed from the prompt? |
| Scaffold identity |
Must match the claimed drawn structures |
No (structures not shown) |
| Substituent identity/position |
Must match exact substituents |
No |
| Stereochemistry |
If drawings define absolute stereochemistry, mismatch can avoid |
No |
| Salt form |
“pharmaceutically acceptable salt” often captures many salts |
No (salt scope not specified) |
| Polymorph/hydrate/solvate |
Usually separate patents unless claim covers solid forms |
No |
| Equivalent compounds |
Closed “group consisting of” can narrow doctrine-of-equivalents leverage |
Partially (language suggests closed group, but members unknown) |
| Prosecution history estoppel |
Depends on arguments during prosecution |
No |
Key Takeaways
- The excerpted claims for US 9,579,324 indicate a closed group of specific compounds (free base/acid or pharmaceutically acceptable salts) defined by structural formulas in dependent claims 2–6.
- The claim language provided supports a conclusion that the patent is chemical-entity focused, not primarily method-of-use or formulation focused.
- A complete patent landscape for the relevant API, including Orange Book status, Paragraph IV challenges, expiration timing, litigation, settlement terms, and adjacent patent families, cannot be produced from the provided claim excerpt because the actual chemical structures and patent identifiers beyond the number are missing.
FAQs
- Does US 9,579,324 cover salts only or does it also cover free base/acid forms?
- How does “group consisting of” in a compound claim affect infringement for close analogs?
- Can a generic avoid a compound-of-formula patent by launching a different polymorph or solvate form?
- How do PTA and PTE typically change US patent expiration dates in FDA-regulated drugs?
- What is the usual relationship between compound formula patents and later salt/polymorph patents in the same family?
References
- US Patent 9,579,324 (claims excerpt provided in prompt).
More… ↓
⤷ Start Trial
|
